nitumumab. Enlisting Dr. Nenvak's help. Vogelstein and the PED designed a mathematical model from the tumorous tissue of 28 colon cancer patients at Johns I Iopkins about to embark on a course of paninunumab treatment. Nowak's findings were extraordinary: they showed that even before treatment began. less than .

nitumumab. Enlisting Dr. Nenvak's help. Vogelstein and the PED designed a mathematical model from the tumorous tissue of 28 colon cancer patients at Johns I Iopkins about to embark on a course of paninunumab treatment. Nowak's findings were extraordinary: they showed that even before treatment began. less than .